BL 3730
Alternative Names: BL-3730Latest Information Update: 01 May 2003
At a glance
- Originator Dainippon Pharmaceutical
- Class
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple organ failure; Reperfusion injury; Respiratory distress syndrome
Most Recent Events
- 30 Apr 2001 Preclinical development for Multiple organ failure in Japan (Unknown route)
- 30 Apr 2001 Preclinical development for Reperfusion injury in Japan (Unknown route)
- 30 Apr 2001 Preclinical development for Respiratory distress syndrome in Japan (Unknown route)